Guided Therapeutics announced that Stem World Enterprises, its distributor for East Africa, has been awarded a contract with the Nairobi County Health Services Sector to supply the first LuViva Advanced Cervical Scan for the agency’s cervical cancer screening program.
"We are pleased to partner with Stem World Enterprises and Nairobi County to bring the latest technology for screening of cervical disease that leads to cancer to the women of East Africa," said Gene Cartwright, CEO and President of Guided Therapeutics.
"Based on the leadership of Nairobi and their commitment to improving health services, we believe that more and more women across Africa will benefit from the advantages of LuViva, which in turn will support our inroads into other parts of the developing world."
"Nairobi County Health Services Sector is a true innovator for healthcare in East Africa as demonstrated by the incorporation of LuViva into their cervical cancer screening program," said Alphonce Omondi, CEO of Stem World.
The LuViva program could potentially expand to six additional facilities in the county with up to 10,000 patients per month being screened.
LuViva is a technologically advanced diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue.
Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing.
LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva Cervical Guide single-use patient interface and calibration disposable.